Corvus Pharmaceuticals (NASDAQ:CRVS) Price Target Raised to $14.00

Corvus Pharmaceuticals (NASDAQ:CRVS) had its target price upped by Oppenheimer from $8.00 to $14.00 in a research report report published on Wednesday,Benzinga reports. They currently have an outperform rating on the stock.

Other analysts have also recently issued reports about the company. StockNews.com cut Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, October 31st. Mizuho raised Corvus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Tuesday, October 22nd. Finally, LADENBURG THALM/SH SH lifted their price objective on shares of Corvus Pharmaceuticals from $12.00 to $21.00 and gave the company a “buy” rating in a research note on Monday, September 16th. One analyst has rated the stock with a sell rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $12.83.

Corvus Pharmaceuticals Trading Down 3.9 %

Shares of NASDAQ:CRVS opened at $8.19 on Wednesday. The firm’s 50 day moving average is $6.75 and its two-hundred day moving average is $4.00. The firm has a market capitalization of $512.28 million, a P/E ratio of -8.81 and a beta of 1.05. Corvus Pharmaceuticals has a 52 week low of $1.30 and a 52 week high of $10.00.

Institutional Investors Weigh In On Corvus Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the company. Nwam LLC bought a new stake in shares of Corvus Pharmaceuticals in the 3rd quarter worth $53,000. XTX Topco Ltd acquired a new position in Corvus Pharmaceuticals during the third quarter worth about $74,000. Avity Investment Management Inc. raised its position in Corvus Pharmaceuticals by 138.2% in the third quarter. Avity Investment Management Inc. now owns 27,580 shares of the company’s stock worth $146,000 after acquiring an additional 16,000 shares in the last quarter. Oppenheimer & Co. Inc. bought a new stake in Corvus Pharmaceuticals in the third quarter worth about $89,000. Finally, Towerview LLC lifted its holdings in Corvus Pharmaceuticals by 4.6% in the 2nd quarter. Towerview LLC now owns 400,000 shares of the company’s stock valued at $728,000 after acquiring an additional 17,500 shares during the last quarter. 46.64% of the stock is currently owned by institutional investors and hedge funds.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.